萬盛股份(603010.SH):擬出資384萬元與百葵鋭、合盛投資共設盛鋭生物
格隆匯6月17日丨萬盛股份(603010.SH)公佈,公司擬與百葵鋭(深圳)生物科技有限公司(簡稱“百葵鋭”)、嘉興合盛投資合夥企業(有限合夥)(由公司核心管理人員組建的合夥企業,簡稱“合盛投資”,具體名稱以市場監督管理局最終核准為準)共同投資設立深圳盛鋭生物科技有限公司(簡稱“盛鋭生物”,具體名稱以市場監督管理局最終核准為準)。盛鋭生物的註冊資本為800萬元,本次投資公司擬認繳出資384萬元,認繳出資比例為48%;百葵鋭擬認繳出資280萬元,認繳出資比例為35%;合盛投資擬認繳出資136萬元,認繳出資比例為17%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.